Novo Nordisk
NVO
#15
Rank
ยฃ429.00 B
Marketcap
ยฃ97.16
Share price
-5.46%
Change (1 day)
26.18%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of June 2024 : ยฃ6.25 B

According to Novo Nordisk's latest financial reports the company's total debt is ยฃ6.25 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ3.13 B2.29%
2022-12-31ยฃ3.06 B2.39%
2021-12-31ยฃ2.99 B139.04%
2020-12-31ยฃ1.25 B147.57%
2019-12-31ยฃ0.50 B719.06%
2018-12-31ยฃ61.84 M-69.4%
2017-12-31ยฃ0.20 B668.97%
2016-12-31ยฃ26.27 M-75.21%
2015-12-31ยฃ0.10 B40.32%
2014-12-31ยฃ75.54 M213.41%
2013-12-31ยฃ24.1 M-56.04%
2012-12-31ยฃ54.82 M-42.65%
2011-12-31ยฃ95.6 M-62.94%
2010-12-31ยฃ0.25 B54.88%
2009-12-31ยฃ0.16 B-44.91%
2008-12-31ยฃ0.30 B125.91%
2007-12-31ยฃ0.13 B-2.38%
2006-12-31ยฃ0.13 B-44.53%
2005-12-31ยฃ0.24 B52.58%
2004-12-31ยฃ0.16 B-1.96%
2003-12-31ยฃ0.16 B28.6%
2002-12-31ยฃ0.12 B-25.66%
2001-12-31ยฃ0.17 B-1.56%
2000-12-31ยฃ0.17 B-4.64%
1999-12-31ยฃ0.18 B-25.24%
1998-12-31ยฃ0.24 B-12.2%
1997-12-31ยฃ0.28 B40.78%
1996-12-31ยฃ0.19 B

Total debt for similar companies or competitors

Company Total debt differencediff. Country
ยฃ52.32 B 736.11%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.01 B 251.75%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ41.14 B 557.48%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ19.40 B 209.97%๐Ÿ‡ซ๐Ÿ‡ท France